| Candidates | Company |
| Forxiga (Dapagliflozin) | AstraZeneca |
| Viekira Pak (Ombitasvir) | Abbvie |
| Lynparza (Olaparib) | AstraZeneca |
| Otezla (Apremilast) | Celgene |
| Forsteo (Teriparatide) | Lilly |
| Imbruvica (Ibrutinib) | Janssen |
| Trulicity (Dulaglutide) | Lilly |
| Candidates | Company |
| Evolocumab (Repata) | Amgen |
| Yervoy (Ipilimumab) | Bristol-Myers Squibb |
| Sovriad (Simeprevir) | Janssen |
| Beyodaim (Pertuzumab+Trastuzumab) | Roche |
| Zelboraf (Vemurafenib) | Roche |
| Candidates | Company |
| Opsumit (Macitentan) | Actelion |
| BLINATUMOMAB | Amgen |
| Candidates | Company |
| Absorb™ Bioresorbable Vascular Scaffold | Abbott |
| Johnson & Johnson – OneTouch Verio® IQ | Johnson & Johnson |
| Candidates | Company |
| Nanoencapsulated colistin | BIND |
| Triazavirin | Institute of Organic Synthesis |
| Mobilan Mobilan (M-VM3) | Panacela Labs |
| Candidates | Company |
| “Femoflor®”+ “ImmunoQuantex®” | DNA |
| Triazavirin | Institute of Organic Synthesis |
| Seroguard | Pharmasyntez |
